Vaccine Advisory Panel Recommends Wider Use of RSV, Two New Vaccines.

 

A 3D rendering of the respiratory syncytial virus. NIAID

A committee of independent vaccine experts voted Wednesday to recommend lowering the age at which adults can get the respiratory syncytial virus vaccine, potentially opening up access to the vaccine to adults in their 50s who are at higher risk of severe illness from RSV.

The Advisory Committee on Immunization Practices voted to recommend that any adult RSV vaccine that is licensed by the Food and Drug Administration for use in high-risk adults ages 50 to 59 be recommended for use in that age group. If the recommendation is accepted by the Centers for Disease Control and Prevention — which the ACIP advises — insurance companies would be required to cover the cost of the vaccine for eligible individuals.

It’s unclear how quickly that could happen. The ACIP’s recommendations must be approved by the CDC director, and currently, the agency does not have a director. Susan Monres, who was serving as acting director until she was nominated for the position, has not yet gone through the Senate confirmation process.

A spokesman said CDC Chief of Staff Matthew Bazzelli will receive the committee’s six recommendations that emerged from Wednesday’s meeting.

Jeremy Fast, a Boston emergency room physician and public health expert who writes the weekly column Inside Medicine, reported last week that legal experts say that in the CDC director’s absence, Health Secretary Robert F. Kennedy Jr. could sign off on the committee’s recommendations.

In addition to the RSV vaccine vote, the committee also recommended the use of a new meningococcal vaccine from GSK, Bavarian Nordic’s chikungunya vaccine and voted to amend previous recommendations for another chikungunya vaccine made by Valneva.

If accepted by the CDC, the vote on the use of RSV vaccines in people in their 50s would initially apply to vaccines sold by GSK and Pfizer. Moderna is in the process of applying to the FDA to add people ages 50 to 59 to its RSV vaccine license, and the new policy — if approved — would cover them as well.

A cost-benefit analysis conducted by researchers at the CDC and the University of Michigan suggested that using these expensive vaccines in select members of this age group could result in cost savings. Specifically, it suggested that people who have had a lung transplant, or who have heart failure, chronic obstructive pulmonary disease, chronic kidney disease, or severe obesity, should be considered for RSV vaccination in their 50s.

About 30 percent of American adults ages 50 to 59 would be eligible, said CDC vaccine researcher Michael Melger.

The current CDC recommendation for use of these vaccines in older adults is that anyone 75 years of age or older should get the shot, and anyone 60 to 74 years of age who is at high risk of severe illness from RSV should get the shot. The ACIP has been slow to recommend broader use of the RSV vaccine for older adults due to some concerns.

Two vaccines — Pfizer and GSK products — appear to be associated with an increased risk of Guillain-Barré syndrome. (There have been no reports of GBS in people who received the Moderna vaccine.)

Another concern relates to the fact that it is not yet known how often these vaccines will need to be given, and whether getting a booster dose at a later date will provide a sufficient boost in protection. Data to date suggest that although booster doses do lead to a rise in antibodies, antibody levels do not return to the levels seen after the first shot with these vaccines.

The current recommendation for RSV vaccines is that they be a one-time shot, although it is widely expected that additional shots will be recommended at some point in the future.

The committee also voted to recommend the use of a new chikungunya vaccine, Vimconia, for travelers and scientists who work in laboratories with the chikungunya virus. The vaccine, made by Bavarian Nordic, is licensed for use in people 12 years of age and older.

Chikungunya infection, which is triggered by the bite of an infected mosquito, causes fever and muscle and joint pain that can be severe and, in some cases, long-lasting. Transmission has been recorded in about 120 countries worldwide, although the disease occurs in outbreaks that are unpredictable in their frequency.

The recommendation is that the vaccine can be used in people who are traveling to a country where there is an outbreak. The committee further recommended that the use of the vaccine could be considered for people who are traveling to a location where the risk of transmission is high if the person will be staying in that location for six months or more.

The committee had previously recommended the use of another chikungunya vaccine, made by Valneva. Earlier recommendations emphasized use in people 65 years of age and older, who are at increased risk of serious illness if infected with the virus.

But six reports of serious side effects in older adults after vaccination — five of which required hospitalization — prompted the committee to revise that recommendation on Wednesday. While it did not recommend against the use of Valneva in people 65 years of age and older, if the recommendation is accepted, caution would be exercised about the use of the vaccine in that age group.

The committee also recommended the use of GSK's pentavalent — one in five — vaccine for people aged 16 to 23 for whom a vaccine is recommended to protect against meningitis and for people aged 10 and older who are at increased risk of meningococcal disease due to underlying medical conditions.

Read more

China's 84% Retaliatory Tariffs: A Bold Response to U.S. Trade Tensions

 

Introduction

In a dramatic escalation of trade tensions, China has recently imposed retaliatory tariffs of 84% on U.S. goods. This decisive move marks a significant shift in the complex economic relationship between the two global powerhouses. As the trade war intensifies, industry experts and policymakers alike are analyzing the implications of these steep tariffs on global markets. In this blog post, we dive into the details behind China's latest action, explore the strategic motivations, and examine its potential impact on both national economies and international trade.

The Context Behind the Tariff Decision

For years, the U.S. and China have engaged in a tit-for-tat dispute over trade practices, intellectual property rights, and market access. The U.S. government, under former President Trump’s administration, introduced a series of tariffs aimed at addressing perceived unfair trade practices and reducing the trade deficit. In response, China’s recent decision to apply an 84% tariff rate on U.S. goods represents a robust form of countermeasure designed to pressure American exporters and signal China’s willingness to defend its economic interests aggressively.

Understanding the Focus Keywords: China Tariffs, Retaliatory Tariffs, and U.S. Goods

By employing the focus keywords—China tariffs, retaliatory tariffs, and U.S. goods—this article provides a comprehensive analysis aimed at clarifying the strategic rationale behind China's actions. These tariffs are not merely a fiscal tool; they signify a broader negotiation tactic intended to recalibrate the dynamics of U.S.-China economic relations.

Unpacking the 84% Tariff Rate

An 84% tariff is not just a number—it’s a powerful message. This rate dramatically increases the cost of American products entering the Chinese market, aiming to deter U.S. businesses from exporting their goods at current volumes. By targeting a substantial portion of U.S. exports, China is effectively forcing American companies to reconsider their pricing structures, supply chain decisions, and long-term market strategies.

Economic and Political Implications

1. For U.S. Businesses:
   The new tariffs could lead to a significant reduction in sales, as American products become less competitive in one of the world's largest markets. Companies may need to absorb higher costs or pass them along to consumers, potentially dampening demand.
   
   

2. For China’s Market:
   While the tariffs serve as a tool for negotiation, they also risk disrupting established supply chains. Chinese industries that rely on U.S. components or raw materials might face increased production costs, contributing to inflationary pressures.
   
   

3. Global Trade Dynamics:
   In a world where supply chains are interdependent, the backlash could extend beyond U.S.-China trade. Other nations might find themselves caught in the crossfire as global markets adjust to the new economic climate.
   
   

---

China’s Strategic Motives

China's decision to implement these retaliatory tariffs can be seen as part of a broader strategy. Here are a few key considerations:

• Protecting Domestic Industries:
  By imposing high tariffs, China aims to shield its own manufacturing sector from external pressures, promoting local products over foreign imports.
  
  

• Negotiation Leverage:
  The tariffs serve as a bargaining chip in future trade negotiations. China signals that any further U.S. actions may result in even stronger countermeasures, urging a more balanced dialogue.
  
  

• Long-term Trade Reconfiguration:
  This move may prompt both countries to reconsider the foundational structures of their trade relationships. With supply chains in flux, businesses could pivot towards diversification strategies, reducing reliance on any single trade partner.
  
  

Industry Reactions and Market Trends

Global markets have been quick to react to this development, with immediate impacts observed in stock indices and commodity prices. U.S. manufacturers, particularly those in sectors heavily reliant on exports to China, are expressing concern over potential revenue losses. Additionally, economists warn that this escalation could trigger a broader price surge, affecting everyday consumers both domestically and internationally.

A Closer Look at Affected Sectors

• Technology:
  High-tech products, a vital export for the U.S., face potential setbacks as Chinese consumers and businesses look elsewhere for more cost-effective alternatives.
  
  

• Agriculture:
  American farmers, already grappling with fluctuating prices, may see their products become less attractive in the Chinese market, further straining an already delicate economic balance.
  
  

• Automotive:
  The automotive industry, characterized by complex global supply chains, might experience delays and increased production costs, leading to longer-term implications for both manufacturers and consumers.
  
  

Potential Long-term Impact

The imposition of an 84% tariff is unlikely to be an isolated incident. Instead, it could herald a series of tit-for-tat measures that might reshape global trade policies. Analysts suggest that while the short-term effects will be pronounced, the long-term consequences may lead to a gradual restructuring of international trade agreements and supply networks.

Countries around the world will have to adapt, with businesses likely exploring new markets and regions to circumvent potential disruptions. The shockwaves of this policy could accelerate a reorientation toward more localized production, diversifying trade partners beyond the traditional U.S.-China axis.

Moving Forward: What to Expect

As both nations recalibrate their economic strategies, businesses and consumers must brace for further changes. Policymakers will face mounting pressure to negotiate a resolution that averts a prolonged trade war. Here’s what we might expect in the coming months:

• Increased Diplomatic Engagement:
  U.S. and Chinese officials are likely to engage in high-stakes negotiations aimed at diffusing tensions and establishing more mutually beneficial trade terms.
  
  

• Market Diversification:
  Companies will explore alternative markets to mitigate the impact of these tariffs. This shift could lead to new trade relationships with emerging economies in Asia, Africa, and Latin America.
  
  

• Technological Adaptation:
  Advances in technology may aid businesses in streamlining operations and reducing production costs, helping to alleviate some of the economic burdens imposed by the tariffs.
  
  

• Revisiting Trade Agreements:
  The situation might catalyze a revisiting of long-standing trade agreements, with a push toward more balanced policies that address the concerns of both nations.
  
  

Conclusion

China’s decision to impose retaliatory tariffs of 84% on U.S. goods represents a critical juncture in the ongoing trade tensions between the two economic giants. With significant implications for a range of industries, this bold action is both a shield for domestic interests and a strategic move in international negotiations. As the global community watches intently, the unfolding dynamics of this trade dispute will undoubtedly shape the future landscape of international commerce. Stakeholders on both sides must remain agile, adapting their strategies to navigate the evolving economic environment.

FAQs

1. What triggered China to impose an 84% tariff on U.S. goods?
The tariffs are a response to U.S. trade policies, particularly measures implemented during the Trump administration aimed at addressing trade imbalances and alleged unfair practices.

2. Which U.S. sectors are most affected by these tariffs?
Key sectors likely impacted include technology, agriculture, and automotive manufacturing, all of which face increased costs and market challenges.

3. How might the new tariffs affect global trade?
The imposition of steep tariffs could disrupt global supply chains, prompt shifts in trade partnerships, and potentially lead to a broader economic realignment.

4. What does this mean for U.S. consumers?
Higher tariffs may lead to increased product costs, which could ultimately be passed on to consumers in the form of higher prices on imported goods.

5. Could these actions lead to further trade negotiations between the U.S. and China?
Yes, this aggressive move is likely intended as a bargaining chip, pressuring both sides into renewed, high-stakes trade negotiations aimed at achieving a more balanced economic relationship.

Read more